共 55 条
[1]
Alicikus ZA(2011)Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer Cancer 117 1429-1437
[2]
Yamada Y(2015)What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation Radiother Oncol 115 295-300
[3]
Zhang Z(2019)Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial Int J Radiat Oncol Biol Phys 104 790-797
[4]
Zaorsky NG(2014)Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial Lancet Oncol 15 464-473
[5]
Palmer JD(2014)Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival Radiother Oncol 110 104-109
[6]
Hurwitz MD(2016)Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991 J Clin Oncol 34 1748-1756
[7]
Pasalic D(2018)Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial JAMA Oncol 4 e180039-333
[8]
Kuban DA(2019)Ten-year outcomes of moderately hypofractionated (70 Gy in 28 fractions) intensity modulated radiation therapy for localized prostate cancer Int J Radiat Oncol Biol Phys 104 325-367
[9]
Allen PK(2014)Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer BJU Int 114 360-790
[10]
Dearnaley DP(2016)Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c–T2N0M0 prostate cancer Int J Clin Oncol 21 783-404